<DOC>
	<DOCNO>NCT02331251</DOCNO>
	<brief_summary>The Phase Ib II cohort enroll patient metistatic solid tumor . Phase II enroll follow patient : Patients metastatic sarcoma enrol follow 4 arm : pembro plus gemcitabine , pembro plus gemcitabine docetaxel , pembro plus gemcitabine vinorelbine , pembro plus liposomal doxorubicin . Patients metastatic pancreatic adenocarcinoma enrol pembro plus gemcitabine nab-paclitaxel arm . Patients extensive-stage small cell lung cancer enrol pembro plus irinotecan arm . Patients ER+ breast cancer enrol pembro vinorelbine arm . Patients ovarian cancer enrol pembroplus liposomal doxorubicin arm . Patients metastatic TNBC ( ER/PR/HER2 negative ) enrol pembro plus gemcitabine arm .</brief_summary>
	<brief_title>Study Pembrolizumab Plus Chemotherapy Patients With Advanced Cancer ( PembroPlus )</brief_title>
	<detailed_description>Pembrolizumab 2mg/kg administer intravenously 30 minute every 3 week .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patient least 18 year old definitive histologically cytologically confirm metastatic solid tumor 2 . Patient one metastatic tumor measurable CT scan ( PET/CT , patient allergic CT contrast medium ) 3 . The investigator select appropriate treatment arm patient follow requirement : ( ) Patients prior progression intolerance single agent chemotherapy enrol arm single agent chemotherapy plus pembro ( b ) The chemotherapy arm select must consider standard care list NCCN guideline ( www.nccn.org ) cancer type 4 . Have recover acute toxicity prior treatment : 1 . &gt; 3 week must elapse since receive investigational agent 2 . &gt; 2 week must elapse since receive radiotherapy , ≥ 3 week 5 halflives whichever shorter treatment cytotoxic biologic agent ( ≥ 6 week mitomycin nitrosoureas ) . Chronic treatment noninvestigational gonadotropinreleasing hormone analog hormonal supportive care permit 5 . Patient adequate biological parameter demonstrate follow blood count time screening : 6 . Absolute neutrophil count ( ANC ) &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 9 g/dL 7 . Serum creatinine ≤2.0 , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 5 time upper limit normal ( ULN ) range ( except : nabpaclitaxel contain arm , bilirubin ≤ 1.25 time ULN docetaxel contain arm , bilirubin must within institutional normal limit AST/ALT ≤ 1.5 time ULN ) 8 . Thyroid stimulate hormone ( TSH ) within institutional normal limit . If TSH upper limit normal range , free T4 within institutional normal limit acceptable 9 . Persistent prior systemic therapy nonhematologic AE grade ≥ 2 ( except alopecia correctable electrolyte abnormality supplementation ) 10 . Patient Karnofsky performance status ( KPS ) ≥ 70 11 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 4 month follow last dose pembrolizumab 30 day follow last dose chemotherapy trial , must negative urine serum pregnancy test within 2 week prior begin treatment trial Phase II 1 . Patients must metastatic sarcoma enrol follow 4 arm : pembro plus gemcitabine , pembro plus gemcitabine docetaxel , pembro plus gemcitabine vinorelbine , pembro plus liposomal doxorubicin 2 . Patients must metastatic pancreatic adenocarcinoma enrol pembro plus gemcitabine nabpaclitaxel arm 3 . Patients must extensivestage small cell lung cancer enrol pembro plus irinotecan arm 1 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 2 . Serious nonhealing wound , ulcer , bone fracture 3 . Patient known brain metastasis , unless previously treat wellcontrolled least 1 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement 5 . Patient know active infection HIV , hepatitis B , hepatitis C ( patient NOT require test presence virus prior therapy protocol ) 6 . Requiring daily corticosteroid dose ≥ 10 mg prednisone equivalent per day 7 . Patient undergone major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study 8 . Patient history allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindication Special Warnings Precautions section product comparator SmPC Prescribing Information 9 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity 10 . Patient receive anticancer therapy participation trial 11 . Prior treatment pembro . Receipt PD1 inhibitor PDL1 inhibitor allow 12 . Active prior document autoimmune disease require systemic treatment within past 2 year Phase II portion 1 . Patients history one primary cancer , exception : 1. curatively resect nonmelanomatous skin cancer ; 2. curatively treated cervical carcinoma insitu ; 3. primary solid tumor treat curative intent know active disease present treatment administer 2 year prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>